POS0058-PARE INCREASING PREECLAMPSIA KNOWLEDGE IN SLE WITH A SPECIFIC EDUCATIONAL TOOL: PRELIMINARY RESULTS

Background: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia but recent studies suggest aspirin is used only in a minority SLE pregnancies. There an urgent need improve counselling management this vulnerable population. Objectives: We conducting the PREPARE (PREeclamPsia knowledge & adheRence prEgnancies) trial, randomized controlled trial (RCT) evaluating educational tool on adherence among pregnant SLE. present preliminary analyses effect knowledge. Methods: Consecutive recruited until 16th gestational week 5 Canadian Systemic Lupus International Collaborating Clinics centres (i.e. Montreal, Halifax, Quebec, Winnipeg, Calgary) since 05/2018. Subjects randomly assigned receive either specifically-designed (intervention group) or standard care (control group). At baseline first trimester) second trimester visits, participants complete self-administered questionnaires (scored out 30 by research team blinded intervention). restricted current analysis enrolled Montreal (accounting for nearly half total planned sample size). performed univariate linear regression assess mean score difference between two groups from visit). Results: Thirty-three were included study, which 16 exposed intervention 17 unexposed. Baseline characteristics well balanced similar age group (32.2 years, deviation, SD, 4.6) control (34.1 SD 4.2) identical proportion subjects post-secondary education 80%). The scores visits was 4.4 points (95% CI -0.1, 9.0) 1.5 -2.7, 5.7). (from those receiving 2.7 higher -1.5, 6.9) than care. Conclusion: Approximately midway into we observed trend improvement visit who received compared group, although CIs null. Our RCT well-poised provide new evidence-based approach SLE, could help optimize use outcomes References: [1]Schramm AM, Clowse ME. prevention pregnancy. Autoimmune Dis. 2014;2014:920467. doi:10.1155/2014/920467 [2]Bujold E, Roberge S, Lacasse Y, et al. Prevention intrauterine growth restriction started early pregnancy: meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402-414. doi:10.1097/AOG.0b013e3181e9322a [3]Andreoli L, Bertsias GK, Agmon-Levin N, EULAR recommendations women’s health family planning, assisted reproduction, pregnancy menopause patients and/or antiphospholipid syndrome. Ann Rheum 2017 Mar;76(3):476–85. doi: 10.1136/annrheumdis-2016-209770. [4]Mendel A, Bernatsky SB, Hanly JG, Low prevalence factors multinational inception cohort. 2019;78(7):1010-1012. doi:10.1136/annrheumdis-2018-214434 Disclosure Interests: None declared.